All News

Leflunomide

ICYMI: 9 Facts about Leflunomide

Jack Cush, MD

Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. Here are some highpoints from this Medscape article and lecture.

Read Article
MRI.kneepain.jpg

ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

Jack Cush, MD

EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).

Read Article
Malar,rash,SLE, Lupus

ICYMI: JAMA: SLE Review

Jack Cush, MD

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Read Article
pills-14550__180_0.jpg

Factors Affecting Hydroxychloroquine Adherence

Jack Cush, MD

A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. 

Read Article
GCA,woman

JAK Inhibitors in Giant Cell Arteritis

Jack Cush, MD

Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care.

Read Article
kidney-147499_640.png

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis

Jack Cush, MD

A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.

Read Article
mtx.png (keep)

No Risk of Interstitial Lung Disease with Methotrexate Use

Jack Cush, MD

JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).

Read Article
JAK Janus

New indications for JAK inhibitors

Janet Pope, MD, MPH, FRCPC

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
RT @yuz6yusof #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare

Dr. John Cush RheumNow ( View Tweet)

Future Big BiTEs (6.28.2024) Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on https://t.co/V10S4oVFsv. https://t.co/AKb2qmQ2nf https://t.co/3nKuEXteXS

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew "I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events. Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early! #EULAR2024 OP0114 @karolinskainst

Dr. John Cush RheumNow ( View Tweet)

Factors Affecting Hydroxychloroquine Adherence A study from the University of British Columbia has evaluated the trajectories of HCQ use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. https://t.co/kDUxVCfRGt https://t.co/1v79Vqdqo8

Links:

Dr. John Cush RheumNow ( View Tweet)
No Risk of Interstitial Lung Disease with Methotrexate Use JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM). https://t.co/qauRelAkG0 https://t.co/bhSLYrfzlv

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/QbLBMtBO30 https://t.co/b63bC0SKsf

Links:

Dr. John Cush RheumNow ( View Tweet)
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (&amp; good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020

Dr. John Cush RheumNow ( View Tweet)

RT: @synovialjoints In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150

Dr. John Cush RheumNow ( View Tweet)

No Risk of Interstitial Lung Disease with Methotrexate Use JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM). https://t.co/MslJk5TARw https://t.co/BUUiqC8jaQ

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n&gt;100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/45OM0PLtjM

Links:

Dr. John Cush RheumNow ( View Tweet)

Abatacept Misses on Shingrix Response Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria. https://t.co/rNOARWzEcI https://t.co/xebXgsouta

Links:

Dr. John Cush RheumNow ( View Tweet)
BiTEs (Bispecific T cell engagers) kill B cells by engaging T cells. IV blinatumomab (CD19xCD3 BiTE) rx of 6 refractory RA pts, led to B & T cell depletion, rapid decline Dz activity, synovitis, autoAbs & was safe, w/ brief temp & ^CrP w/ 1st rx https://t.co/ebLsknirtQ https://t.co/eEIch4g0I1

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×